Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017.
ANRS CO4-FHDH
DAA
HCV incidence rate
HIV
MSM
cohort study
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
28
9
2021
Statut:
ppublish
Résumé
BackgroundDespite the availability of highly effective direct-acting antivirals (DAAs) and the expected treatment as prevention (TasP) effect, transmission of hepatitis C virus (HCV) persists in men who have sex with men (MSM) who engage in high-risk sexual behaviours.AimWe aimed to estimate the incidence of primary HCV infection among MSM living with HIV in France when DAA was readily available.MethodsWe used data from a large French hospital cohort of persons living with HIV (ANRS CO4-FHDH) prospectively collected between 2014 and 2017. HCV incidence rates were calculated using person-time methods for HCV-negative MSM at inclusion who had serological follow-up from 1 January 2014 to 31 December 2017. Sensitivity analyses were performed by varying the main assumptions to assess their impact on the results.ResultsOf 14,273 MSM living with HIV who were initially HCV-seronegative, 330 acquired HCV during follow-up over 45,866 person-years (py), resulting in an overall estimated incidence rate of 0.72/100 py (95% CI: 0.65-0.80). HCV incidence significantly decreased from 0.98/100 py (95% CI: 0.81-1.19) in 2014 to 0.45/100 py (95% CI: 0.35-0.59) in 2017 (54% decrease; 95% CI: 36-67). This trend was confirmed by most of the sensitivity analyses.ConclusionThe primary incidence of HCV was halved for MSM living with HIV between 2014 and 2017. This decrease may be related to unrestricted DAA availability in France for individuals living with HIV. Further interventions, including risk reduction, are needed to reach HCV micro-elimination in MSM living with HIV.
Identifiants
pubmed: 34558403
doi: 10.2807/1560-7917.ES.2021.26.38.2001321
pmc: PMC8462035
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
AIDS. 2018 May 15;32(8):1077-1082
pubmed: 29438195
J Hepatol. 2020 May;72(5):855-864
pubmed: 31862485
Open Forum Infect Dis. 2020 Jan 12;7(1):ofaa019
pubmed: 32016128
AIDS Res Hum Retroviruses. 2007 Jun;23(6):769-76
pubmed: 17604539
Liver Int. 2018 Jun 30;:
pubmed: 29959866
J Hepatol. 2017 Aug;67(2):255-262
pubmed: 28412290
Clin Infect Dis. 2019 Nov 27;69(12):2127-2135
pubmed: 30810158
AIDS. 2010 Jul 31;24(12):1799-812
pubmed: 20601854
AIDS. 2018 Aug 24;32(13):1871-1879
pubmed: 29927787
AIDS. 2007 May 11;21(8):983-91
pubmed: 17457092
J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):105-110
pubmed: 31169768
Open Forum Infect Dis. 2015 Aug 06;2(3):ofv115
pubmed: 26634219
HIV Med. 2016 Feb;17(2):83-8
pubmed: 26548563
Int J Epidemiol. 2014 Oct;43(5):1425-36
pubmed: 24550249
Clin Microbiol Infect. 2020 Jun;26(6):785.e1-785.e4
pubmed: 32035235
Int J Antimicrob Agents. 2020 Jul;56(1):105527
pubmed: 30145247
AIDS. 2020 Jan 1;34(1):47-52
pubmed: 31789889
PLoS One. 2011;6(12):e29322
pubmed: 22216248
AIDS. 2015 Nov;29(17):2335-45
pubmed: 26258525
AIDS. 2008 Oct 1;22(15):1979-91
pubmed: 18784461
Gut. 2020 Oct 27;:
pubmed: 33109688
AIDS. 2009 Jul 31;23(12):F1-7
pubmed: 19542864
AIDS. 2011 May 15;25(8):1083-91
pubmed: 21537114
Hepatology. 2018 Mar;67(3):847-857
pubmed: 29108121
Gastroenterology. 2009 May;136(5):1609-17
pubmed: 19422083
PLoS One. 2019 Mar 13;14(3):e0213526
pubmed: 30865722
Clin Infect Dis. 2018 Apr 17;66(9):1360-1365
pubmed: 29186320
Clin Infect Dis. 2021 Jan 27;72(2):233-238
pubmed: 32211763